A phase 1b, multicenter, two-part, open-label study of Trastuzumab Deruxtecan, an anti-human epidermal growth factor receptor-2 (HER2)-Antibody drug conjugate(ADC), in combination with Nivolumab, an anti-PD-1 Antibody, for subjects with HER2-expressing advanced breast and ...Mehr…
A Multicenter, Open-label, Dose-escalating, Phase I Trial with GEM3PSCA, a PSCA Targeted Bispecific Antibody Engaging T-cells, in Patients with Progressive Disease after Standard Systemic Therapy in Cancers with Positive PSCA Marker.Mehr…
